ArticleAnnals of internal medicine2014
The changing burden of hepatitis C virus infection in the United States: model-based predictions.
Article in Annals of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03038763 (Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers), which is not on this map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Global Burden and Changing Trend of Hepatitis C Virus Infection in HIV-Positive and HIV-Negative MSM: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update.BMC infectious diseases · 2019Pooled it
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.PharmacoEconomics · 2016Pooled it
- Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.Journal of medical virology · 2018Trial
- Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.Journal of viral hepatitis · 2017Trial
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.The Journal of infectious diseases · 2015Trial
- Dissecting incidence and mortality inequalities of six types of liver diseases in 39 alcohol-dominant countries and 93 virus-dominant countries under the aging context: Insights from the Global Burden of Disease Study 2021.Translational oncology · 2026Article
- Quantifying the Contribution of Viral Hepatitis Control Policies and Improvement of Hepatitis C Treatment in Japan during 2000-2030 based on Simulation Modelling.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States.BMC health services research · 2023Article
- New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years.World journal of gastroenterology · 2021Review
- Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.JAMA network open · 2021Article
- A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China.Clinical liver disease · 2021Article
- Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals.Internal medicine (Tokyo, Japan) · 2021Article
- Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.JAMA network open · 2020Article
- Review
- Mortality trend due to Hepatitis B and C in the city of São Paulo, 2002-2016.Revista de saude publica · 2020Article
- A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management.Health care management science · 2019Article
- Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.Scientific reports · 2019Article
- Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment.Digestive diseases and sciences · 2019Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundChronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease.
objectiveTo predict the effect of new therapies and screening on chronic HCV infection and associated disease outcomes.
designIndividual-level state-transition model.
settingExisting and anticipated therapies and screening for HCV infection in the United States. PATIENTS: Total HCV-infected population in the United States. MEASUREMENTS: The number of cases of chronic HCV infection and outcomes of advanced-stage HCV infection.
resultsThe number of cases of chronic HCV infection decreased from 3.2 million in 2001 to 2.3 million in 2013. One-time birth-cohort screening beginning in 2013 is expected to identify 487,000 cases of HCV infection in the next 10 years. In contrast, 1-time universal screening could identify 933,700 cases. With the availability of highly effective therapies, HCV infection could become a rare disease in the next 22 years. Recently approved therapies for HCV infection and 1-time birth-cohort screening could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular carcinoma, 126,500 liver-related deaths, and 9900 liver transplantations by 2050. Increasing the treatment capacity would further reduce the burden of HCV disease. LIMITATION: Institutionalized patients with HCV infection were excluded, and empirical data on the effectiveness of future therapies and on the future annual incidence and treatment capacity of HCV infection are lacking.
conclusionNew therapies for HCV infection and widespread implementation of screening and treatment will play an important role in reducing the burden of HCV disease. More aggressive screening recommendations are needed to identify a large pool of infected patients. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.